PRESS RELEASES

Date Title View
Toggle Summary Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus
- CMX521 is Active In Vitro Against All Strains of Norovirus Tested - - Oral Dosing of CMX521 Inhibited Norovirus Replication in Animal Model - DURHAM, N.C. , June 12, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical
View HTML
Toggle Summary Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox
DURHAM, N.C. , June 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation for brincidofovir for the treatment
View HTML
Toggle Summary Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)
DURHAM, N.C. , June 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey , MD, MPH will deliver remarks before the House Committee on
View HTML
Toggle Summary Chimerix Announces First Quarter 2018 Financial Results
- Landmark AdVance Study Demonstrates Strong Correlation Between  Adenovirus Burden and Mortality Risk - - Site Initiations for AdAPT Study of Oral Short-course Brincidofovir for Adenovirus and IV Brincidofovir Programs Are Progressing – - First Presentation on CMX521 for Norovirus in June- -
View HTML
Toggle Summary Chimerix to Present at the Deutsche Bank 43rd Annual Health Care Conference
DURHAM, N.C. , May 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will
View HTML
Toggle Summary Chimerix to Announce First Quarter 2018 Financial Results on May 7, 2018
DURHAM, N.C. , April 30, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Monday, May 7, 2018 at 8:30 a.m.
View HTML
Toggle Summary Chimerix to Present at the H.C. Wainwright Annual Global Life Sciences Conference
DURHAM, N.C. , April 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that Garrett Nichols , M.D., M.S., Chief Medical Officer of Chimerix will present at the H.C.
View HTML
Toggle Summary Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors
DURHAM, N.C. , March 29, 2018 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the appointment of Martha J. Demski as Chair of the Board of Directors. Martha will succeed Ernest Mario , PhD, who is
View HTML
Toggle Summary The AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden and Mortality Risk
European, multi-center study reinforces need for effective therapies for adenovirus in immunocompromised patients DURHAM, N.C. , March 19, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 38th Annual Health Care Conference
DURHAM, N.C. , March 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will
View HTML